Company Overview - IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology and a leading supplier of equipment and services in proton therapy, which is the most advanced form of radiation therapy available today [6] - The company is also a key player in industrial sterilization, radiopharmaceuticals, and dosimetry [6] - IBA is based in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people worldwide [6] - The company is listed on the pan-European stock exchange EURONEXT [7] Upcoming Financial Results - IBA will publish its consolidated results for the half year 2025 on Thursday, 28 August 2025 at 7am CEST [2] - A conference call and webcast will be hosted by IBA's management team on the same day at 3pm CEST, which will include a Q&A session [3] - The presentation will be available on IBA's investor relations website shortly before the call [4]

Company Overview - IBA (Ion Beam Applications S.A.) is a global leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry [5][6] - The company is headquartered in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people worldwide [5] - IBA is recognized as a certified B Corporation (B Corp), meeting high standards of verified social and environmental performance [5] Shareholder Information - The total capital of IBA is EUR 42,502,318.54, with 30,282,218 securities conferring voting rights [2] - The existing voting rights amount to 40,516,629, which is the denominator for calculating the quota of voting rights that can trigger notification requirements [2] - The statutory ceiling for voting at general meetings is set at 35% of the total voting rights, equating to 14,180,820.2 votes [5] Voting Rights and Regulations - IBA has introduced loyalty voting rights, which apply to registered shares held for at least two consecutive years [3] - The calculation method for loyalty voting rights is based on the LIFO (last in, first out) principle [4] - The company must publish changes in the number of voting rights at the end of each calendar month when such changes occur [1][2]

Group 1 - IBA has initiated a share buyback program to repurchase up to 650,000 ordinary shares to fulfill obligations under long-term incentive plans for management and certain personnel [2][3] - The company repurchased a total of 16,651 shares between May 27 and May 28, 2025, at an average price of €12.19 per share, totaling €203,014.21 [3] - The total number of treasury shares held by IBA amounts to 1,015,552, representing 3.35% of total issued shares, which are 30,282,218 [3] Group 2 - IBA is a leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry [4] - The company is based in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people globally [4] - IBA is listed on the pan-European stock exchange EURONEXT [5]